Drug Trial Radar · NCT05907954
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Jul 3, 2023
Primary completion
Apr 30, 2027
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- IDEAYA BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Conditions
- Uveal Melanoma
Interventions
DarovasertibDrug
Oral, potent, selective inhibitor of Protein Kinase C
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs) and significant laboratory abnormalitiesTime frame: from first dose to 28 days after last dose of therapy, approximately 18 months
- Cohort 1 (enucleation): Number of patients converted from requiring enucleation to radiationTime frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
- Cohort 2 (plaque brachytherapy): Estimated change in modeled radiation doseTime frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
- Cohort 3 (patients with small UM tumors): Number of patients with clinical benefit per protocol-defined UM response criteriaTime frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months
Locations
18 sites in 7 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
Moores Cancer Center
La Jolla, California
Stanford Cancer Institute
Palo Alto, California
University of Miami
Miami, Florida
The Cancer and Hematology Centers
Grand Rapids, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Northwell
Manhasset, New York
Thomas Jefferson University
Philadelphia, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
St. Vincent's Health Sydney
Sydney, New South Wales, Australia
Alfred Health
Melbourne, Victoria, Australia
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Institute Curie
Paris, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Fondazione IRCCS Istituto Nazionale Tumori
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy
Leiden University Medical Center
Leiden, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.